Overview and Scope
Diffuse large B-cell lymphoma therapeutics refer to the treatment approaches and medications used to manage and combat diffuse large B-cell lymphoma, a type of non-Hodgkin lymphoma characterized by rapidly growing cancerous B-cells.
Sizing and Forecast
The diffuse large b-cell lymphoma therapeutics market size has grown strongly in recent years. It will grow from $4.4 billion in 2023 to $4.8 billion in 2024 at a compound annual growth rate (CAGR) of 8.9%. The growth in the historic period can be attributed to clinical research advances, regulatory approvals, patient awareness and diagnosis, collaborative initiatives, standard of care evolution.
The diffuse large b-cell lymphoma therapeutics market size is expected to see strong growth in the next few years. It will grow to $6.49 billion in 2028 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to biomarker discovery, immunotherapy advancements, rising incidence rates, global aging population, healthcare infrastructure development, expanded access to novel drugs. Major trends in the forecast period include rise of outpatient treatment settings, collaborative clinical trials, patient-centric care models, advances in diagnostic imaging, healthcare digitalization..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/diffuse-large-b-cell-lymphoma-therapeutics-global-market-report
Segmentation & Regional Insights
The diffuse large b-cell lymphoma therapeutics market covered in this report is segmented –
1) By Drug Class: Cisplatin, Carboplatin, 5-fluorouracil, Docetaxel, Paclitaxel, Methotrexate, Other Drugs
2) By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy, Other Therapies
3) By Route of Administration: Oral, Parenteral, Other Routes
4) By End User: Hospitals, Clinics, Other End-Users
North America was the largest region in the global diffuse large B-cell lymphoma therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the diffuse large b-cell lymphoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10805&type=smp
Major Driver Impacting Market Growth
The increasing incidence of diffuse large B-cell lymphoma (DLBCL) is expected to propel the growth of the diffuse large B-cell lymphoma therapeutics market going forward. Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive cancer that originates from B-cells in the lymphatic system and is characterized by rapid and diffuse growth. It is a type of non-Hodgkin lymphoma (NHL). The diffuse large B-cell lymphoma therapeutics help to improve outcomes for individuals already diagnosed with the condition by targeting and managing the cancer cells. For instance, the American Cancer Society, a US-based voluntary health organization, estimated that in 2023, about 80,550 people (44,880 males and 35,670 females) will be diagnosed with non-Hodgkin’s lymphoma (NHL), where about 20,180 people will die from NHL. Therefore, the increasing incidence of diffuse large B-cell lymphoma (DLBCL) drives the growth of the diffuse large B-cell lymphoma therapeutics market.
Key Industry Players
Major companies operating in the diffuse large b-cell lymphoma therapeutics market report are Novartis AG, Pfizer Inc., Merck & Co Inc., GlaxoSmithKline plc, F. Hoffmann-La Roche AG, CTI BioPharma Corp., Celltrion Healthcare Co Ltd., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences Inc., Seagen Inc., Kite Pharma Inc., ADC Therapeutics SA, Bayer AG, Erytech Pharma SA, Xencor Inc., Denovo Biopharma LLC, Calithera Biosciences Inc., IMV Inc., Biogen Inc., Autolus Therapeutics plc, Allogene Therapeutics Inc., Spectrum Pharmaceuticals Inc., AstraZeneca PLC, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Aptevo Therapeutics Inc., Takeda Pharmaceutical Company Limited, Johnson & Johnson, Celgene Corporation, Eli Lilly and Company, Sanofi SA, Seattle Genetics Inc., Karyopharm Therapeutics Inc., TG Therapeutics Inc., MorphoSys AG,
The diffuse large b-cell lymphoma therapeutics market report table of contents includes:
1. Executive Summary
2. Diffuse Large B-cell Lymphoma Therapeutics Market Characteristics
3. Diffuse Large B-cell Lymphoma Therapeutics Market Trends And Strategies
4. Diffuse Large B-cell Lymphoma Therapeutics Market – Macro Economic Scenario
5. Global Diffuse Large B-cell Lymphoma Therapeutics Market Size and Growth
…..
31. Global Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Benchmarking
32. Global Diffuse Large B-cell Lymphoma Therapeutics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Diffuse Large B-cell Lymphoma Therapeutics Market
34. Diffuse Large B-cell Lymphoma Therapeutics Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
https://topprnews.com/remote-health-monitoring-market-trends/
https://topprnews.com/sports-medicine-market-growth/
https://topprnews.com/surgical-dressing-market-trends/
https://goodprnews.com/protein-a-resin-market-size/
https://goodprnews.com/public-safety-and-security-market-growth/
https://goodprnews.com/reach-stacker-market-trends/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
